TAGRISSO 40 mg, film-coated tablet 30 tablets
Active ingredients: Osimertinib mesylate, Osimertinib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TAGRISSO 40 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) aluminium de 1 comprimé(s)
- Marketing authorisation holder
- ASTRAZENECA AB
- Reimbursement according to BDPM
- 100 %
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Certains types de cancers des bronches. ; JOURNAL OFFICIEL ; 26/07/19
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Apr 2016
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60368512CIP73004764CIP133400930047644Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉSYLATE D'OSIMERTINIBcomprimé | 47,7 mg · un comprimé | SA |
| OSIMERTINIBcomprimé | 40 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.